Louisiana State Employees Retirement System Invests $2.23 Million in Hims & Hers Health, Inc. (NYSE:HIMS)

Louisiana State Employees Retirement System acquired a new stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS) during the fourth quarter, Holdings Channel.com reports. The fund acquired 92,400 shares of the company’s stock, valued at approximately $2,234,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. State Street Corp grew its position in Hims & Hers Health by 4.7% during the third quarter. State Street Corp now owns 4,626,543 shares of the company’s stock valued at $85,221,000 after purchasing an additional 206,078 shares in the last quarter. Geode Capital Management LLC grew its position in Hims & Hers Health by 12.7% in the third quarter. Geode Capital Management LLC now owns 4,289,549 shares of the company’s stock worth $79,029,000 after acquiring an additional 482,177 shares in the last quarter. Wellington Management Group LLP grew its position in Hims & Hers Health by 34.5% in the third quarter. Wellington Management Group LLP now owns 3,444,414 shares of the company’s stock worth $63,446,000 after acquiring an additional 883,230 shares in the last quarter. Charles Schwab Investment Management Inc. grew its position in Hims & Hers Health by 15.1% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,667,422 shares of the company’s stock worth $30,714,000 after acquiring an additional 218,566 shares in the last quarter. Finally, Verition Fund Management LLC grew its position in Hims & Hers Health by 15.0% in the third quarter. Verition Fund Management LLC now owns 645,731 shares of the company’s stock worth $11,894,000 after acquiring an additional 84,316 shares in the last quarter. 63.52% of the stock is owned by hedge funds and other institutional investors.

Hims & Hers Health Stock Performance

Shares of HIMS stock opened at $60.41 on Friday. Hims & Hers Health, Inc. has a 52-week low of $9.22 and a 52-week high of $64.84. The stock has a market cap of $13.20 billion, a price-to-earnings ratio of 137.31 and a beta of 1.35. The firm has a fifty day moving average of $32.06 and a 200-day moving average of $24.26.

Insider Activity

In other news, insider Soleil Boughton sold 2,343 shares of the company’s stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $29.90, for a total value of $70,055.70. Following the sale, the insider now owns 165,254 shares of the company’s stock, valued at approximately $4,941,094.60. This represents a 1.40 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Andrew Dudum sold 33,513 shares of the company’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $33.38, for a total transaction of $1,118,663.94. Following the completion of the sale, the chief executive officer now directly owns 33,502 shares in the company, valued at approximately $1,118,296.76. The trade was a 50.01 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 1,111,554 shares of company stock worth $33,865,763. 17.71% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several analysts have commented on HIMS shares. Needham & Company LLC boosted their target price on shares of Hims & Hers Health from $28.00 to $31.00 and gave the stock a “buy” rating in a research report on Monday, January 6th. TD Cowen reissued a “buy” rating and issued a $28.00 target price on shares of Hims & Hers Health in a research report on Wednesday, November 20th. Morgan Stanley began coverage on shares of Hims & Hers Health in a research note on Tuesday, December 17th. They issued an “overweight” rating and a $42.00 price objective for the company. Deutsche Bank Aktiengesellschaft boosted their price objective on shares of Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a research note on Wednesday, November 6th. Finally, Canaccord Genuity Group boosted their price objective on shares of Hims & Hers Health from $28.00 to $38.00 and gave the stock a “buy” rating in a research note on Monday, December 2nd. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, Hims & Hers Health currently has an average rating of “Hold” and a consensus target price of $25.13.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.